Center-Authored Papers

Filters: Author is Voorhees, Peter M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S et al..  2013.  A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
R
van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.  2015.  A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.. Oncotarget. 6(30):30408-30419. Abstract
Y
Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE, Burke JN et al..  2016.  Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.. The Lancet. Oncology. 17(11):1569-1578. Abstract